Aileron Therapeutics, Inc.

NasdaqCM:ALRN Stock Report

Market Cap: US$90.8m

Aileron Therapeutics Future Growth

Future criteria checks 0/6

Aileron Therapeutics's earnings are forecast to decline at 8.5% per annum while its annual revenue is expected to grow at 100% per year. EPS is expected to grow by 50% per annum.

Key information

-8.5%

Earnings growth rate

50.0%

EPS growth rate

Biotechs earnings growth20.7%
Revenue growth rate100.0%
Future return on equityn/a
Analyst coverage

Low

Last updated01 Dec 2023

Recent future growth updates

Recent updates

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aug 18
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Dec 30
Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Aileron Therapeutics: An Assessment On A Lottery Ticket

Oct 21

Aileron Therapeutics: Solving Chemotherapy's Toxicity

May 01

Aileron Therapeutics +31% on insider buying more shares

Jan 08

Aileron raises $40M via equity offering

Jan 06

Aileron Therapeutics EPS in-line

Nov 13

Earnings and Revenue Growth Forecasts

NasdaqCM:ALRN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-38N/AN/A1
12/31/2025N/A-32N/AN/A1
12/31/2024N/A-27N/AN/A1
12/31/2023N/A-16-20-20N/A
9/30/2023N/A-13-14-14N/A
6/30/2023N/A-17-19-19N/A
3/31/2023N/A-24-22-22N/A
12/31/2022N/A-27-25-25N/A
9/30/2022N/A-30-27-27N/A
6/30/2022N/A-30-27-27N/A
3/31/2022N/A-28-25-25N/A
12/31/2021N/A-26-24-24N/A
9/30/2021N/A-24-22-22N/A
6/30/2021N/A-23-20-20N/A
3/31/2021N/A-21-21-21N/A
12/31/2020N/A-21-20-20N/A
9/30/2020N/A-23-22-22N/A
6/30/2020N/A-26-24-24N/A
3/31/2020N/A-29-25-25N/A
12/31/2019N/A-29-27-26N/A
9/30/2019N/A-29-29-27N/A
6/30/2019N/A-29-31-27N/A
3/31/2019N/A-31-33-28N/A
12/31/2018N/A-32-32-28N/A
9/30/2018N/A-31-30-27N/A
6/30/2018N/A-30-26-25N/A
3/31/2018N/A-26-22-22N/A
12/31/2017N/A-23-21-21N/A
9/30/2017N/A-20N/A-19N/A
6/30/2017N/A-18N/A-18N/A
3/31/2017N/A-19N/A-17N/A
12/31/2016N/A-18N/A-15N/A
9/30/2016N/A-17N/A-14N/A
6/30/2016N/A-16N/A-12N/A
3/31/2016N/A-14N/A-12N/A
12/31/2015N/A-13N/A-12N/A
9/30/2015N/A-13N/A-13N/A
6/30/2015N/A-13N/A-12N/A
3/31/2015N/A-15N/A-15N/A
12/31/2014N/A-16N/A-17N/A
12/31/2013220N/A-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALRN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALRN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALRN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALRN is forecast to have no revenue next year.

High Growth Revenue: ALRN is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALRN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.